Blunted PTH response to Vitamin D Insufficiency/deficiency and Colorectal Neoplasia Risk
Clinical Nutrition https://doi.org/10.1016/j.clnu.2020.10.057
Jacklyn N.HellwegePh.Da1XiangzhuZhuM.Da1XiangHuangPh.DaMartha J.ShrubsolePh.DaLeiFanbBingshanLiPh.D, M.DcReidNessM.DdDouglas L.SeidnerM.DdEdward L.GiovannucciScDeTodd L.EdwardsPh.DaQiDaiPh.Da
Opinion
When Vitamin D gets to the parathyroid cells the PTH is reduced
4 genes can block vitamin D from getting to cells- such as the parathroid and the colon
If Vitamin D is blocked to the parathyroid then it can also be blocked to the colon
Genetics category listing contains the following
see also
384 articles in Vitamin D Receptor 140 articles in Vitamin D Binding Protein = GC 35 articles in CYP27B1 - Topical Vitamin D
- Nanoemulsion Vitamin D may be a substantially better form
- Getting Vitamin D into your body
Vitamin D blood test misses a lot
- Snapshot of the literature by Vitamin D Life as of early 2019
- Vitamin D from coming from tissues (vs blood) was speculated to be 50% in 2014, and by 2017 was speculated to be 90%
- Note: Good blood test results (> 40 ng) does not mean that a good amount of Vitamin D actually gets to cells
- A Vitamin D test in cells rather than blood was feasible (2017 personal communication)
- Commercially available 2019
- However test results would vary in each tissue due to multiple genes
- Good clues that Vitamin D is being restricted from getting to the cells
1) A vitamin D-related health problem runs in the family- especially if it is one of 51+ diseases related to Vitamin D Receptor
2) Slightly increasing Vitamin D show benefits (even if conventional Vitamin D test shows an increase)
3) Vitamin D Receptor test (<$30) scores are difficult to understand in 2016- easier to understand the VDR 23andMe test results analyzed by FoundMyFitness in 2018
4) Back Pain- probably want at least 2 clues before taking adding vitamin D, Omega-3, Magnesium, Resveratrol, etc
- The founder of Vitamin D Life took action with clues #3&4
Background & Aims
In contrast to many observational studies, large-scale randomized trials do not support the protective role of vitamin D for the prevention of colorectal neoplasia. However, in previous studies, individuals with blunted parathyroid hormone (PTH) response to vitamin D insufficiency/deficiency (BPRVID), were not differentiated from those with high PTH response to vitamin D insufficiency/deficiency (HPRVID). Individuals with BPRVID are responsive to magnesium treatment, particularly treatment of magnesium plus vitamin D while those with HPRVID are responsive to vitamin D treatment. We prospectively compared these two distinct groups (i.e. BPRVID and HPRVID) for risk of incident adenoma, metachronous adenoma, and incident colorectal cancer (CRC)Methods
Three nested case-control studies in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.Results
We found optimal 25(OH)D levels were associated with a significantly reduced risk of CRC, primarily among women. The associations between 25(OH)D and CRC risk significantly differed by PTH levels, particularly among women. Compared to individuals with optimal levels for both 25(OH)D and PTH, all others were at an elevated risk of incident CRC, primarily in women. We found those with BPRVID had 2.56-fold significantly increased risk of CRC compared to 1.65-fold non-significantly increased risk for those with HPRVID. Among women, we observed those with BPRVID had 4.79 to 6.25-fold significantly increased risks of incident CRC and adenoma whereas those with HPRVID had 3.65-fold significantly increased risk of CRC.Conclusions
Individuals with BPRVID are at higher risks of incident adenoma and CRC compared to those with HPRVID, particularly among women.Increased Colorectal cancer risk if Vitamin D does not lower PTH (Vit D not getting to cells) – Nov 2020Printer Friendly PDF this page! Follow this page for updates98 visitors, last modified 06 Nov, 2020, This page is in the following categories (# of items in each category)